LB Pharmaceuticals has granted Christopher Zergebel, its new Senior Vice President of Clinical Operations, an inducement equity award of 75,000 stock options. The options have a ten-year term, an exercise price of $32.95 per share, and vest over four years. This grant is part of the Nasdaq Listing Rule 5635(c)(4) inducement exception to attract key talent. LB Pharmaceuticals is advancing its lead drug candidate LB-102 for neuropsychiatric disorders, with ongoing Phase 3 and Phase 2 clinical trials targeting schizophrenia and bipolar depression.
Travelzoo has announced new exclusive travel deals for its Canadian Club Members, featuring discounted packages to destinations like Portugal, the Maldives, British Columbia, and Antigua. Offers include a $799 Portugal coastal getaway with flights, a...
US stock markets closed last week with strong gains, led by the Dow, Nasdaq, and S&P 500, all maintaining levels above their rising 52-week averages. Investors are closely watching upcoming inflation reports (CPI and PPI) and earnings from tech compa...
XRP Ledger (XRPL) has proposed six protocol upgrades, including a key privacy feature called 'Confidential Transfers' aimed at institutional users. These upgrades require 80% validator approval over two weeks to activate, with voting currently ongoin...
MARA has obtained $600 million in new debt by pledging 18,750 Bitcoin, valued at about $1.2 billion, to finance its expansion into power generation and AI infrastructure. The loans come from Coinbase Credit and Two Prime Lending, with combined princi...
American Superconductor's Q1 FY26 results revealed strong growth in its Wind segment but weakness in its legacy Grid and NWL businesses, causing revenue shifts and margin compression. Despite impressive headline growth and improving profit margins, t...
